Biology Reference
In-Depth Information
252. Pavese JM, Farmer RL, Bergan RC. Inhibition of cancer cell
invasion and metastasis by genistein.
Cancer Metastasis Rev
2010;
264. Reed AM, Fishel ML, Kelley MR. Small-molecule inhibitors of
proteins involved in base excision repair potentiate the anti-
tumorigenic effect of existing chemotherapeutics and irradiation.
Future Oncol
2009;
82.
253. Kovacic P, Somanathan R. Multifaceted approach to resveratrol
bioactivity: Focus on antioxidant action, cell signaling and safety.
Oxid Med Cell Longev
2010;
29
(3):465
e
26.
265. O'Shaughnessy J, Osborne C, Pippen J. Final efficacy and safety
results of a randomized phase II study of the PARP inhibitor
iniparib (BSI-201) in combination with gemcitabine/carboplatin
in metastatic triple negative breast cancer.
Proceedings of the 35th
European Society of Medical Oncology
; 2010. Abstract LBA11.
266. Krokan HE, et al. Properties and functions of human uracil-DNA
glycosylase from the UNG gene.
Prog Nucleic Acid Res Mol Biol
2001;
5
(5):713
e
100.
254. Hanahan D, Weinberg RA. The hallmarks of cancer.
Cell
2000;
100
3
(2):86
e
70.
255. Hoeijmakers JH. Genome maintenance mechanisms for pre-
venting cancer.
Nature
2001;
(1):57
e
74.
256. Damia G, D'Incalci M. Targeting DNA repair as a promising
approach in cancer therapy.
Eur J Cancer
2007;
411
(6835):366
e
86.
267. Neddermann P, et al. Cloning and expression of human G/T
mismatch-specific thymine-DNA glycosylase.
J Biol Chem
1996;
271
68
:365
e
801.
257. Karran P. Mechanisms of tolerance to DNA damaging thera-
peutic drugs.
Carcinogenesis
2001;
43
(12):1791
e
7.
258. Sanchez-Perez I. DNA repair inhibitors in cancer treatment.
Clin
Transl Oncol
2006;
22
(12):1931
e
74.
268. Boorstein RJ, et al. Definitive identification of mammalian 5-
hydroxymethyluracil DNA N-glycosylase activity as SMUG1.
J Biol Chem
2001;
(22):12767
e
6.
259. Kinsella TJ. Coordination of DNA mismatch repair and base
excision repair processing of chemotherapy and radiation dam-
age for targeting resistant cancers.
Clin Cancer Res
2009;
8
(9):642
e
7.
269. Petronzelli F, et al. Biphasic kinetics of the human DNA repair
protein MED1 (MBD4), a mismatch-specific DNA N-glycosylase.
J Biol Chem
2000;
276
(45):41991
e
15
(6):
9.
260. Yap TA, et al. Poly(ADP-Ribose) polymerase (PARP) inhibitors:
Exploiting a synthetic lethal strategy in the clinic.
CA Cancer J Clin
2011;
1853
e
9.
270. Radicella J, et al. Cloning and characterization of hOGG1,
a human homolog of the OGG1 gene of.
Saccharomyces cerevisiae.
Proc Natl Acad Sci, USA
1997;
275
(42):32422
e
49.
261. Canan Koch SS, et al. Novel tricyclic poly(ADP-ribose) poly-
merase-1 inhibitors with potent anticancer chemopotentiating
activity: design, synthesis, and X-ray cocrystal structure.
JMed
Chem
2002;
61
(1):31
e
5.
271. Slupska MM, et al. Functional expression of hMYH, a human
homolog of the
Escherichia coli
MutY protein.
J Bacteriol
1999;
181
94
(15):8010
e
3.
272. Aspinwall R, et al. Cloning and characterization of a functional
human homolog of E
scherichia coli
endonuclease III.
Proc Natl
Acad Sci, USA
1997;
(19):6210
e
74.
262. Tikhe JG, et al. Design, synthesis, and evaluation of 3,4-dihydro-
2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as
45
(23):4961
e
inhibitors of poly
14.
273. Jaruga P, et al. Mouse NEIL1 protein is specific for excision of 2,6-
diamino-4-hydroxy-5-formamidopyrimidine and 4,6-diamino-5-
formamidopyrimidine
94
(1):109
e
81.
263. Miyashiro J, et al. Synthesis and SAR of novel tricyclic quinox-
alinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Bioorg Med Chem Lett
2009;
(ADP-ribose) polymerase.
J Med Chem
2004;
47
(22):5467
e
from oxidatively
damaged DNA.
19
(15):4050
4.
Biochemistry
2004;
43
(50):15909
14.
e
e
